Tabernero J, Melero I, Ros W, et al. Phase I studies of the novel carcinoembryonic antigen CD3 T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 35, 2017 (suppl; abstr 3002).
Alectinib versus crizotinib bij ALK-positief NSCLC
jun 2017 | Longoncologie